# MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

> **NCT06412497** · PHASE2 · RECRUITING · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 60 (estimated)

## Conditions studied

- Severe Aplastic Anemia
- Acquired Amegakaryocytic Thrombocytopenia
- Acquired Pure Red Cell Aplasia
- Paroxysmal Nocturnal Hemoglobinuria

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Rabbit ATG
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **RADIATION:** Total Body Irradiation
- **BIOLOGICAL:** Cell Infusion
- **DRUG:** Post-Transplant G-CSF
- **DRUG:** Tacrolimus
- **DRUG:** Mycophenolate Mofetil

## Key facts

- **NCT ID:** NCT06412497
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-05
- **Primary completion:** 2035-05-01
- **Final completion:** 2036-05-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06412497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06412497, "MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06412497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*